← Back to patent-cliff list
奥美沙坦酯/阿折地平
Tier C — Watch / tradeOlmesartan Medoxomil/Azelnidipine
第一三共株式会社
Originator
2010
First approval
-
Expiry (public)
$0.15B ▲
Peak sales
化学药
Type
Targets：AT1、Voltage-gated L-type calcium channel
Brand：Rezaltas
Indications (approved)：高血压
Regional status
US
-
EU
-
China
-
Japan
批准上市
2010-01-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Olmesartan Medoxomil/Azelnidipine?
Approved indications include: 高血压.
When does the Olmesartan Medoxomil/Azelnidipine patent expire?
No public expiry year is available for Olmesartan Medoxomil/Azelnidipine yet; this page updates once verified.
How do I get a quote for Olmesartan Medoxomil/Azelnidipine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24